Perioperative Bleeding Associated With Ibrutinib in Dermatologic Surgery: A Case–Control Study
CONCLUSION
Ibrutinib may be associated with increased risk of bleeding in patients with hematologic malignancies, particularly older men with lower platelet levels and on multiple anticoagulants. Transient discontinuation of ibrutinib should be considered for dermatologic surgeries.
Source: Dermatologic Surgery - Category: Dermatology Tags: Original Article Source Type: research